News

DexCom (DXCM) shares ended the last trading session 9.8% higher at $133.72. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.5% loss over the past four weeks.

The surge in stock price was likely driven by FDA clearance for Stelo glucose biosensor, available over-the-counter to consumers without a prescription. As an alternative for people without insurance coverage for continuous glucose monitoring sensors like G7, Stelo's approval for non-prescription use would further facilitate this population's access to cutting-edge CGM technology.

This medical device company is expected to post quarterly earnings of $0.27 per share in its upcoming report, which represents a year-over-year change of +58.8%. Revenues are expected to be $909.9 million, up 22.7% from the year-ago quarter.

Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.

For DexCom, the consensus EPS estimate for the quarter has been revised 3.7% lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on DXCM going forward to see if this recent jump can turn into more strength down the road.

The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>

DexCom belongs to the Zacks Medical - Instruments industry. Another stock from the same industry, Delcath Systems, Inc. (DCTH), closed the last trading session 1.1% lower at $3.90. Over the past month, DCTH has returned -15.7%.

Delcath Systems, Inc.'s consensus EPS estimate for the upcoming report has remained unchanged over the past month at -$0.67. Compared to the company's year-ago EPS, this represents a change of +22.1%. Delcath Systems, Inc. currently boasts a Zacks Rank of #3 (Hold).

4 Oil Stocks with Massive Upsides

Global demand for oil is through the roof... and oil producers are struggling to keep up. So even though oil prices are well off their recent highs, you can expect big profits from the companies that supply the world with "black gold."

Zacks Investment Research has just released an urgent special report to help you bank on this trend.

In Oil Market on Fire, you'll discover 4 unexpected oil and gas stocks positioned for big gains in the coming weeks and months. You don't want to miss these recommendations.

Download your free report now to see them.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.